TxCell raises cash for first-in-man CAR-Treg cell therapy study

By Gareth Macdonald contact

- Last updated on GMT

iStock/mkos83
iStock/mkos83
TxCell has raised €11m ($11.6m) through a share issue which it will use to fund first-in-man study of one of its cell therapy candidates.

The shares were bought by new backers like Auriga Ventures II and ING Luxembourg a S.A. as well as existing TxCell investors Innobio FCPR and Bpifrance Participation Large Venture.

CEO Stephane Boissel told us "TxCell has realigned its strategy, being the first to move into the Car-Treg field in auto-immune diseases. The finance will help TxCell to get through to a first IND approval to initiate a first-in-man study with a CAR-Treg candidate, which is expected by the end of 2018.

He added that: "This study will be a world first. It most likely would be in solid organ transplantation, to treat or prevent chronic rejection.​ 

TxCell has four CAR-Treg candidates in his pipeline. Three are for the treatment of diseases, specifically lupus nephritis, bullous pemphigoid and multiple sclerosis. The fourth is designed to prevent graft-versus-host disease after transplantation.

All four were developed using the firm’s ENTrIA platform which uses CARs to direct antigen-specific regulatory cells (Ag-Tregs) to target autoimmune inflammatory diseases.

All four are listed as being in early phase development on TxCell’s website.

Two of the therapies, the GvHD treatment – ENTX#SOT – and the lupus candidate ENTX#LN – are the subject of preclinical research accords signed last year.

ENTX#BP, which is being developed as a treatment for the rare skin blistering disease bullous pemphigoid, is also the focus of a preclinical research partnership.

However, when TxCell announced the deal with the Lubeck Institute of Experimental Dermatology (LIED) in June​ it said the aim was to conduct “non-clinical pharmacology studies with CAR-Treg cells to prepare for a first-in-man study​.”

Related news

Show more

Related products

show more

How Viral Safety Testing Will Evolve

How Viral Safety Testing Will Evolve

Viral Safety for mAb: Prevent, Detect, Remove | 20-May-2020 | Event Programme

The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space. Many of the methods used...

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Related suppliers

Follow us

Products

View more

Webinars